Sharemaestro company-news research for Microbot Medical Inc (MBOT), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
MBOT news sentiment
Microbot Medical Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone53Neutral is 50
Balanced news tone
42/100 evidence confidence
100% direct company focus
1 current stories across 1 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 1 fresh independent stories, including 1 company-specific items across 1 publishers.
Latest source headline Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval? finance.yahoo.com · 10 Aug 2026 12:42What supports the read
1 current stories are mapped specifically to MBOT.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
53/100
Weighted toneBalanced news tone
42/100
Evidence confidencebuilding confidence
100%/100
Company focus1 direct stories
N/A/100
Evidence agreementrequires at least 2 stories
News history
Tone and story flow over 21 days
23 Jul02 Aug12 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth12
1.0 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness65
recency-weighted evidenceAgreement0
requires at least 2 storiesSource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings601 stories · 100%
Source mix
Where the evidence comes from
finance.yahoo.com601 stories · 100%
Recurring subjects
Subjects appearing most often
Robotic Surgery1Medtech1Healthcare1Financial Results1Fda Approval1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#160Tone
finance.yahoo.comDirect company coverage
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ
Fda ApprovalFinancial ResultsHealthcareMedtechRobotic Surgery
- Published
- 10 Aug 2026 12:42
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.